IVBT.US Innovation1 Biotech Inc
- Market cap
- USD 4.49K
- P/E
- -
- P/B
- 0.36x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Feb 2024.
Is IVBT.US undervalued?
Graham numberThe Graham number of Innovation1 Biotech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Innovation1 Biotech Inc fundamental analysis
No fundamental analysis for Innovation1 Biotech Inc yet.
Innovation1 Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Innovation1 Biotech Inc
Innovation1 Biotech Inc. focuses on researching, developing, producing, and selling pharmaceutical products. The company offers natural supplements for the treatment of symptoms associated with the flu and long covid under the NutraFlu and Nutravid19 brands; and other supplement and medical nutrition products. It also develops NLC001 that is in Phase II clinical trial for the treatment of long covid and other viral indications. The company is based in New York, New York.
Full company profileInnovation1 Biotech Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 2 quarters up to Feb 29, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Innovation1 Biotech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 16.8K | 79.2K | 1.18K | 3.08K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -64.3K | -50.1K | -1.78K | 1.66K | 0.00 | 0.00 | 0.00 |
| Operating Income | -436K | -667K | -217K | -239K | -5.25M | -1.27M | -612K |
| EBITDA | -973K | -168K | -1.28M | 1.26M | -38.3M | -5.68M | - |
| Net Income | -976K | -170K | -2.58M | 1.04M | -40.9M | -5.99M | -1.09M |
| EPS | -2.27 | -0.39 | -14 | 5.51 | -2.04 | -0.29 | -0.05 |
| Balance Sheet | |||||||
| Total Assets | 863K | 256K | 209K | 182K | 44.0M | 76.0K | 122K |
| Total Liabilities | 687K | 224K | 2.89M | 407K | 41.1M | 3.51M | 3.46M |
| Shareholders' Equity | 176K | 32.4K | -2.68M | -225K | 2.85M | -3.43M | -3.34M |
| Cash & Short-term Investments | 774K | 19.0K | 17.9K | 137K | 156K | 49.8K | 108K |
| Cash Flow | |||||||
| Operating Cash Flow | -443K | -776K | -410K | -30.4K | -3.13M | -620K | -598K |
| Capital Expenditure | 2.47K | 6.56K | 853K | 853K | 853K | 0.00 | 0.00 |
| Free Cash Flow | -445K | -782K | -410K | -30.4K | -3.13M | -620K | -598K |
| Ratios | |||||||
| ROE | -554.7% | -525.5% | - | - | -1,433.0% | - | - |
| ROA | -113.1% | -66.3% | -1,236.8% | 571.7% | -93.0% | -7,880.0% | -897.0% |
| Net Profit Margin | -5,816.7% | -214.6% | -218,464.7% | 33,764.0% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Innovation1 Biotech Inc dividends
Innovation1 Biotech Inc has not paid dividends in the last 6 fiscal years.
Last stock split: 1:308 on Jan 12, 2021.
Who owns Innovation1 Biotech Inc
- Insiders 61.86%
- Institutions 0.00%
- Public & others 38.14%
- Shares outstanding 22.5M
- Free float 8.57M
Innovation1 Biotech Inc company profile
- Company name
- Innovation1 Biotech Inc
- Ticker
- IVBT.US
- Exchange
- USA Stocks
- Sector
- Financial Services
- Industry
- Biotechnology
- Fiscal year end
- August
- Address
- 169 Madison Ave, New York, NY, United States, 10016
- Phone
- 212 292 3115
- Website
- i1bio.com
About Innovation1 Biotech Inc
Innovation1 Biotech Inc. focuses on researching, developing, producing, and selling pharmaceutical products. The company offers natural supplements for the treatment of symptoms associated with the flu and long covid under the NutraFlu and Nutravid19 brands; and other supplement and medical nutrition products. It also develops NLC001 that is in Phase II clinical trial for the treatment of long covid and other viral indications. The company is based in New York, New York.
Innovation1 Biotech Inc management
3- Mr. Francis Knuettel II, M.B.A.Executive Chairman & Interim CEO · born 1966
- Mr. Samuel J. KnipperChief Financial Officer · born 1995
- Tammy PhillipsManaging Director